About the Study

For adults living with symptoms of schizophrenia

The goal of this study is to evaluate the long-term efficacy, safety, and tolerability of CVL-231.
This study is sponsored by Cerevel Therapeutics.

Length of Study:  15-day screening period. 52 weeks open-label treatment period. 28-day follow-up period.
Total length: About 58 weeks.

Eligibility 

You may be eligible to participate in this study if you:

• are between the ages of 18-65 years old
• have been diagnosed with schizophrenia
• have been currently taking medication for schizophrenia for at least 3 consecutive months

If chosen for this study, you will be compensated for every study visit that you complete, and we can provide transportation if needed. 

If you are interested in participating in this clinical trial, please call our friendly staff at 773-989-8313 ext. 116 today. You can also fill out the contact form below.